We are live on
!
Find out more
SCM
Soleus Capital Management Portfolio holdings
AUM
$2.47B
1-Year Est. Return
115.63%
This Fund
S&P 500
This Quarter
Est. Return
+14.15%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$736M
AUM Growth
+$94.9M
(+15%)
Cap. Flow
+$68.2M
Cap. Flow
% of AUM
9.27%
Top 10 Holdings %
Top 10 Hldgs %
43.9%
Holding
93
New
21
Increased
19
Reduced
26
Closed
17
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Illumina
ILMN
|
+$30.8M |
| 2 |
Charles River Laboratories
CRL
|
+$27.9M |
| 3 |
Eli Lilly
LLY
|
+$25.6M |
| 4 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$20.8M |
| 5 |
Envista
NVST
|
+$18.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Viridian Therapeutics
VRDN
|
+$14.8M |
| 2 |
AnaptysBio
ANAB
|
+$13.6M |
| 3 |
United Therapeutics
UTHR
|
+$13.6M |
| 4 |
AngioDynamics
ANGO
|
+$13M |
| 5 |
APEN
Apollo Endosurgery, Inc.
APEN
|
+$11.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.93% |
| 2 | Consumer Staples | 4.27% |
| 3 | Financials | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
76
AngioDynamics
ANGO
$637M
| – | – |
-670,000
| Closed | -$13M |
|
77
AstraZeneca
AZN
$249B
| – | – |
-84,848
| Closed | -$11.2M |
|
78
Cullinan Oncology
CGEM
$1.12B
| – | – |
-95,485
| Closed | -$1.22M |
|
79
Evolus
EOLS
$487M
| – | – |
-810,676
| Closed | -$9.4M |
|
80
Incyte
INCY
$24.3B
| – | – |
-79,700
| Closed | -$6.05M |
|
|
KZR
81
DELISTED
Kezar Life Sciences
KZR
| – | – |
-25,200
| Closed | -$2.08M |
|
82
Lantheus
LNTH
$6.6B
| – | – |
-55,222
| Closed | -$3.65M |
|
83
NovoCure
NVCR
$1.89B
| – | – |
-13,275
| Closed | -$923K |
|
84
Outset Medical
OM
$87.1M
| – | – |
-4,613
| Closed | -$1.03M |
|
85
Penumbra
PEN
$12.8B
| – | – |
-68,800
| Closed | -$8.57M |
|
86
CALL
SkinHealth Systems
SKIN
$86.9M
| – | – |
-1,300,000
| Closed | -$16.7M |
|
87
STAAR Surgical
STAA
$1.17B
| – | – |
-75,094
| Closed | -$5.33M |
|
88
Steris
STE
$22.9B
| – | – |
-37,310
| Closed | -$7.69M |
|
89
Supernus Pharmaceuticals
SUPN
$2.72B
| – | – |
-258,100
| Closed | -$7.46M |
|
90
VistaGen Therapeutics
VTGN
$13.6M
| – | – |
-27,500
| Closed | -$726K |
|
|
CCXI
91
DELISTED
ChemoCentryx, Inc.
CCXI
| – | – |
-154,400
| Closed | -$3.83M |
|
|
HZNP
92
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| – | – |
-77,842
| Closed | -$6.21M |
|
Similar funds
TW
M
SG
FFA
GWM
Q
SIM
QT
Soleus Capital Management's Q3 2022 Portfolio in Review
As of Q3 2022, Soleus Capital Management held 93 positions worth $736M, up 15% from $641M the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Soleus Capital Management deployed $68.2M of net new capital in Q3 2022, opening 21 new positions and adding to 19 existing holdings. Its largest new stake was Illumina: 155,845 shares worth $28.9M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 87% a quarter earlier, followed by Consumer Staples and Financials.
On the sell side, the largest reduction was Viridian Therapeutics, an estimated $14.8M trimmed.
- Soleus Capital Management's largest Q3 2022 buy was Illumina: 155,845 shares worth $28.9M.
- Soleus Capital Management added most to IVERIC bio, Inc. Common Stock in Q3 2022, an estimated $20.8M increase.
- Soleus Capital Management's biggest Q3 2022 reduction was Viridian Therapeutics, cutting an estimated $14.8M.
- Soleus Capital Management fully exited AngioDynamics in Q3 2022, selling an estimated $13M.
- Soleus Capital Management's ten largest holdings make up 44% of its $736M portfolio in Q3 2022.
- Soleus Capital Management opened 21 new positions and closed 17 in Q3 2022.
- Soleus Capital Management's portfolio value rose 15% quarter-over-quarter to $736M.
Based on Soleus Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.